Skip to content

Novavax Shares Rally After Vaccine Said to be 96% Effective Against Original Coronavirus

Novavax’s (NASDAQ: NVAX) share price is up over 20% premarket on Friday after its Covid-19 vaccine was found to be 96% effective in preventing cases of the original coronavirus strain in late-stage trials, the company said.

Novavax shares are trading at $225.40 premarket after a 20.13% move. Before the company announced it was developing a vaccine in 2020, its shares were trading around the $10 mark.

The trial was conducted in the UK and was also found to be 86% effective in protecting against the more contagious coronavirus variant discovered in England.

Overall its effectiveness was around 90% when combining data from both versions of the virus.

The company also conducted a smaller trial in South Africa, with volunteers exposed to another variant circulating in the country. The vaccine was only approximately 55% effective but prevented severe illness and death.

The company s now expected to submit applications for regulatory authorisation in various countries.

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples. 

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.